Example searches

PLXP PLx Pharma, Inc.

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development of clinically validated and patent-protected PLxGuard delivery system. Its products include Vazalore 325 mg and PL1200 Ibuprofen 200 mg. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Houston, TX.

Company profile

Ticker
PLXP
Exchange
NASDAQ
Website
www.plxpharma.com
CEO
Natasha Giordano
Employees
Incorporated in
Delaware
Location
New Jersey
Fiscal year end
Dec 31
Sector
Health Technology > Pharmaceuticals: Other
Industry (SEC)
Pharmaceutical Preparations
Pfizer • Allergan • Merck & Co. • Warner Chilcott • Teva Pharmaceutical Industries • Johnson & Johnson • ELI LILLY & Co • Bristol Myers Squibb • AbbVie • Mylan ...
Former names
Dipexium Pharmaceuticals, Inc., Dipexium Pharmaceuticals, LLC
SEC CIK
0001497504
Corporate docs

PLXP stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Nov 19
22 Feb 20
31 Dec 20

News

Company financial data Financial data

Chart PLXP financial data
Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 41.11K 182.91K 317.56K 287.66K
Net income 1.7M -9.35M -10.86M 2.95M
Diluted EPS 0.09 -1.1 -2.71 0.33
Net profit margin 4145% -5110% -3419% 1024%
Operating income -3.68M -3.85M -2.92M -2.52M
Net change in cash -2.75M -3.06M 10.07M -2.29M
Cash on hand 18.51M 21.26M 24.32M 14.25M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 753.11K 778.66K 20K 0
Net income 896.48K -15.35M -4.91M -18.74M
Diluted EPS 0.1 -2.19 -1.12 -1.99
Net profit margin 119% -1971% -24526%
Operating income -10.96M -15.85M -4.81M -18.76M
Net change in cash -10.15M 7.73M 11.44M -21.81M
Cash on hand 14.25M 24.4M 16.68M 5.23M

Financial data from PLx Pharma earnings reports

Institutional ownership Q3 2019

PLXP institutional ownership history Ownership history
22.2% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 18 19 -5.3%
Opened positions 3 4 -25.0%
Closed positions 4 3 +33.3%
Increased positions 6 6 –
Reduced positions 3 1 +200.0%
13F shares
 Current Prev Q Change
Total value 10.47M 13.94M -24.9%
Total shares 2.03M 1.94M +4.8%
Total puts 0 0 –
Total calls 0 0 –
Total put/call ratio – – –
Largest owners
 Shares Value Change
Park West Asset Management 1.47M $7.51M 0.0%
Vanguard 294.6K $1.5M +102.3%
Renaissance Technologies 68.71K $350K +6.2%
Nottingham Advisors 58.58K $422K 0.0%
Millennium Management 51.96K $265K +4.1%
Heritage Way Advisors 30K $153K +20.0%
Fayez Sarofim & Co 13.73K $70K 0.0%
NTRS Northern Trust 11K $57K -0.9%
BLK BlackRock 9.53K $48K -3.7%
Cranbrook Wealth Management 7.5K $38K 0.0%
Largest transactions
 Shares Bought/sold Change
Vanguard 294.6K +148.95K +102.3%
University Of Texas/texas Am Investment Managment 0 -62.67K EXIT
Heritage Way Advisors 30K +5K +20.0%
Renaissance Technologies 68.71K +4K +6.2%
UBS UBS 1.05K -2.49K -70.3%
Millennium Management 51.96K +2.05K +4.1%
Aperio 0 -1.85K EXIT
Victory Capital Management 1.48K +1.48K NEW
DB Deutsche Bank 0 -1.3K EXIT
Ibex Wealth Advisors 0 -775 EXIT
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Antibe Therapeutics • Aralez Pharmaceuticals • Old API Wind-down
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: analytical, denominator, numerator, packaging
Removed: bankruptcy
From filing 10-Q 2019 Q3

Financial reports

View all
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
10 May 19
10-K/A
2018 FY
Annual report (amended)
2 Apr 19
10-K
2018 FY
Annual report
8 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
10-Q
2018 Q2
Quarterly report
10 Aug 18
10-Q
2018 Q1
Quarterly report
11 May 18
10-K/A
2017 FY
Annual report (amended)
27 Apr 18
10-K
2017 FY
Annual report
23 Mar 18

Current reports

View all
8-K
Regulation FD Disclosure
13 Jan 20
8-K
PLx Pharma Inc. Provides Regulatory Update on VAZALORE
6 Jan 20
8-K
PLx Pharma Inc. Reports Third Quarter2019Results
8 Nov 19
8-K
Submission of Matters to a Vote of Security Holders
19 Aug 19
8-K
Entry into a Material Definitive Agreement
25 Mar 19
8-K
PLx Pharma Inc. Reports Fourth Quarter2018Results
8 Mar 19
8-K
PLx Pharma Inc. Announces Completion of $15 Million Convertible Preferred Stock Financing
20 Feb 19
8-K
PLx Pharma Inc. Announces Adjournment of Special Meeting of Stockholders
14 Feb 19
8-K
Regulation FD Disclosure
7 Jan 19
8-K
PLx Pharma Inc. Announces $15 Million Convertible Preferred Stock Financing
21 Dec 18

Registration and prospectus

View all
S-3
Shelf registration
27 Mar 19
S-3
Shelf registration
25 Mar 19
D
$15M in equity / options / securities to be acquired, sold $15M, 2 investors
4 Mar 19
D
$18.19M in options / securities to be acquired, sold $18.19M, 37 investors
28 Jun 17
424B5
Prospectus supplement for primary offering
12 Jun 17
424B3
Prospectus supplement
17 Mar 17
S-4/A
Registration of securities issued in business combination transactions (amended)
28 Feb 17
425
Business combination disclosure
14 Feb 17
S-4
Registration of securities issued in business combination transactions
25 Jan 17
425
Business combination disclosure
22 Dec 16

Proxies

DEF 14A
Definitive proxy
2 Jul 19
DEFA14A
Additional proxy soliciting materials
13 Feb 19
DEF 14A
Definitive proxy
10 Jan 19
PRE 14A
Preliminary proxy
26 Dec 18
DEF 14A
Definitive proxy
10 Aug 18
DEF 14A
Definitive proxy
4 Apr 16
PRE 14A
Preliminary proxy
23 Mar 16
DEF 14A
Definitive proxy
1 Apr 15

Other

View all
CT ORDER
Confidential treatment order
19 Sep 19
UPLOAD
Letter from SEC
16 Apr 19
EFFECT
Notice of effectiveness
5 Apr 19
EFFECT
Notice of effectiveness
5 Apr 19
CORRESP
Correspondence with SEC
3 Apr 19
CORRESP
Correspondence with SEC
2 Apr 19
CORRESP
Correspondence with SEC
2 Apr 19
CT ORDER
Confidential treatment order
21 Aug 17
EFFECT
Notice of effectiveness
17 Mar 17
CORRESP
Correspondence with SEC
15 Mar 17

Ownership

View all
SC 13D/A
PLx Pharma Inc.
1 Mar 19
SC 13D/A
PLx Pharma Inc.
31 Dec 18
SC 13D
PLx Pharma Inc.
20 Nov 17
SC 13G/A
PLx Pharma Inc.
22 Jun 17
SC 13G
PLx Pharma Inc.
19 Jun 17
SC 13G
PLx Pharma Inc.
1 May 17
SC 13G/A
Dipexium Pharmaceuticals, Inc.
14 Feb 17
SC 13G/A
Dipexium Pharmaceuticals, Inc.
14 Feb 17
SC 13D
Dipexium Pharmaceuticals, Inc.
3 Jan 17
SC 13G/A
Dipexium Pharmaceuticals, Inc.
16 Feb 16